<DOC>
	<DOCNO>NCT00334334</DOCNO>
	<brief_summary>Three dose primary vaccination healthy infant 6 16 week age time first vaccination Streptococcus pneumonia , Neisseria meningitidis Haemophilus influenzae type b .</brief_summary>
	<brief_title>Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' 10-valent Pneumococcal Conjugate Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>male female , include , 616 week ( 42 118 day ) age time first vaccination , free obvious health problem write informed consent obtain parent/guardian subject . use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use entire study period . Planned administration/ administration vaccine foreseen study protocol period start one month dose vaccine ( ) end 7 day dose 1 dose 2 1 month dose 3 . Previous vaccination disease target vaccine use study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Streptococcus pneumonia , vaccine</keyword>
</DOC>